CORT

Corcept Therapeutics Incorporated

$112.10

+1.76% 2026-10-19

Health CareS&P 400

1M 3M 6M 1Y 2Y

CORTSPY

-7.5%

+1.6%

+22.4%

+141.9%

YTD

+222.1%

+42.5%

Grades vs sector

Momentum

81st pct in sector

A-

12-1 return: +56.8%
Percentile within its GICS sector across the S&P 1500.

Growth

90th pct in sector

Revenue growth (YoY): +31.7%
Percentile within its GICS sector across the S&P 1500.

Value

13th pct in sector

D-

Forward E/P: 4.0% · EBITDA/EV: 0.1%
Percentile within its GICS sector across the S&P 1500.

Profitability

44th pct in sector

Profit margin: +6.6% · Return on equity: +8.2%
Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Held by 1 of 3 live models: Momentum Blend.

Momentum Blend

5.4% of the book · Leaders sleeve

Held Momentum Top 15

not ranked (outside this model's universe or screens)

Quality Growth

not ranked (outside this model's universe or screens)

Why it's in Momentum Blend

In the Leaders sleeve: a fast grower breaking out near its highs after an earnings-style gap.

What would knock it out: Exits if it closes below its stop of $103.70; last close $112.10, 8% above it.

Key stats

Market cap$12.1B

P/E (trailing)249.1

P/E (forward)25.4

52-week range28.66 – 126.38

Revenue growth (YoY, latest qtr)+31.7%

Dividend yield0.00%

Analyst consensusBuy (5)

Mean price target$141.00 (+26%)

Valuation & fundamentals

Bottom line

Roughly fairly valued

Model read-out from the numbers below, not advice. Score +0 (DCF counts double).

•DCF (base case)below the price by 14%

▼Forward P/E vs sector25.4x vs median 17.6x

•Piotroski F-score5/9

▲Altman Z42.1 (safe)

▲Net debt / EBITDA-38.1x

▲Analyst target+26% (5 analysts)

Discounted cash flow

Bear

$41

-63%

growth 17% · disc. 8.0% · term. 2.0%

Base

$96

-14%

growth 28% · disc. 7.0% · term. 2.5%

Bull

$208

+86%

growth 35% · disc. 6.0% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Today's price assumes free cash flow grows about 22% a year for 10 years.

Implied

+22%/yr

FCF, last 3 yrs

+6%/yr

FCF, last 5 yrs

-1%/yr

Revenue, last 3 yrs

+24%/yr

Revenue, last 5 yrs

+17%/yr

Same inputs as the DCF above: trailing free cash flow 0.1B, 7.0% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.40 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9× · 98th pct

249.1×
pricier

Forward P/E

sector median 17.6× · 76th pct

25.4×
pricier

EV / EBITDA

sector median 15.8× · 100th pct

1,460.9×
pricier

Price / sales

sector median 3.1× · 92nd pct

14.6×
pricier

Price / book

sector median 3.5× · 94th pct

17.2×
pricier

FCF yield

sector median 4.1% · 17th pct

0.9%
pricier

Forward EPS $4.41 vs trailing $0.45 (+879% expected growth). Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin

98.3%

Operating margin

0.8%

FCF margin

12.9%

Net margin

6.6%

Return on equity

7.8%

Return on invested capital

1.6%

Net debt / EBITDA

-38.1×

Current ratio

2.9×

Interest cover

3.8×

Cash conversion (OCF/NI)

2.0×

Piotroski F-score 5/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 42.1 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$141

+26%

Analysts

Buy

Range

$50–$165

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$761.4M	$99.7M	$141.8M
2024	$675.0M	$141.2M	$196.1M
2023	$482.4M	$106.1M	$126.5M
2022	$401.9M	$101.4M	$119.9M
2021	$366.0M	$112.5M	$167.4M
2020	$353.9M	$106.0M	$150.7M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +23.7%.

Earnings

Next report: 2026-11-04 · during market · EPS est 0.84

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-07-29	0.06	0.36	+535.3%
2026-04-30	-0.14	-0.30	-111.3%
2026-02-24	0.33	0.20	-39.4%
2025-11-04	0.14	0.16	+18.5%
2025-07-31	0.19	0.29	+54.7%
2025-05-05	0.14	0.17	+19.3%
2025-02-26	0.42	0.26	-38.6%
2024-10-30	0.29	0.41	+41.4%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$256.1M	+31.7%
2026-03-31	$164.9M	–
2025-12-31	$202.1M	–
2025-09-30	$207.6M	–
2025-06-30	$194.4M	–

Analyst actions

HC Wainwright & Co.

2026-09-18 · reit

Buy → Buy
PT $165

Piper Sandler

2026-07-30 · reit

Overweight → Overweight
PT $165

Canaccord Genuity

2026-07-30 · main

Buy → Buy
PT $161

HC Wainwright & Co.

2026-07-30 · main

Buy → Buy
PT $165

Canaccord Genuity

2026-07-29 · main

Buy → Buy
PT $150

Wolfe Research

2026-07-27 · down

Peer Perform → Underperform
PT $50

Insider trades

Wilson James N

Director · 2026-10-15

SELL
$761.7K

Wilson James N

Director · 2026-10-15

SELL
$351.5K

Wilson James N

Director · 2026-10-15

SELL
$34.9K

Vieira Roberto Wandenkolk

President, Oncology · 2026-10-02

SELL
$126.0K

Vieira Roberto Wandenkolk

President, Oncology · 2026-10-02

SELL
$241.4K

Vieira Roberto Wandenkolk

President, Oncology · 2026-10-02

SELL
$600.1K

Lyon Joseph Douglas

See Remarks · 2026-10-02

SELL
$514.4K

Lyon Joseph Douglas

See Remarks · 2026-10-02

SELL
$552.9K

Maduck Sean

See Remarks · 2026-10-02

SELL
$1.8M

Maduck Sean

See Remarks · 2026-10-02

SELL
$1.0M

Lyon Joseph Douglas

See Remarks · 2026-10-01

SELL
$93.5K

Maduck Sean

See Remarks · 2026-10-01

SELL
$47.7K

News

The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics

Zacks · 22h ago

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains

Zacks · Oct 16

Why Healthcare Stocks Are Hot When the AI Trade Runs Cold

Barrons.com · Oct 15

Stats refreshed 2026-10-19 17:47:01 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic StrategiesSystematic equity research and model portfolios.
Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.

What is Coteau?Disclaimer Terms Privacy Data status